

23 May 2024

ASX Announcement

Nasodine Composition Patent Granted in South Africa

- **Nasodine pharmaceutical composition patent granted in South Africa**
- **Already granted in Australia and also filed in other key markets**
- **Patent covers the Nasodine formulation and extends patent overall coverage to 2041**

Firebrick Pharma Limited (ASX: FRE) (the **Company** or **Firebrick**) is pleased to announce that a patent covering the unique formulation of Nasodine® Nasal Spray ("Nasodine") has been granted in South Africa.

The patent is titled: "Improved Virucidal Formulations" and expires in June 2041. The patent has also been filed in the US, Europe and a number of other key markets.

The other Nasodine patent families are 'method-of-use' patents covering the intranasal use of povidone-iodine (PVP-I) for the common cold and pandemic viral diseases. The current patent covers the pharmaceutical composition of Nasodine, regardless of specific intended use.

The basis for the invention claimed in the patent is that the proprietary Nasodine formulation displays enhanced virucidal activity compared with PVP-I solutions alone. According to the patent, the Nasodine formulation "showed a markedly increased virucidal activity compared to other PVP-I formulations (concentrations between around 0.5% and 1.0%), at clinically-relevant exposure times of 2 and 5 minutes."

The patent also discloses that the Nasodine formulation had enhanced antiviral activity against SARS-CoV-2 (COVID-19 virus), when compared with aqueous PVP-I solution.

A range of formulations is covered in the accepted patent claims, notably including PVP-I concentrations between 0.10% and 1.25%.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -



About Firebrick Pharma

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine. The Company has successfully developed a povidone-iodine nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials for the nasal spray, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com